Sales revenue of Tallinna Sadam in 2025 was 119 million euros. Adjusted EBITDA was close to 57 million euros and profit more than 22 million euros. Comparing to the preceding year sales revenue decreased slightly by –0.8% but adjusted EBITDA increased by +6% and profit by +17%. Sales revenue in the fourth quarter was more than 29 million euros, adjusted EBITDA was 11 million euros and profit 3.6 million euros. Comparing to the same period last year sales revenue increased by +1.3%, adjusted EBITDA decreased ...

BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (year-over-year comparisons unless otherwise noted) Net revenue of $1,465.4 million, up 8.8%Net income of $58.5 million, down 2.7%GAAP diluted earnings p ...

Core Viewpoint - RingCentral, Inc. (RNG) shares have surged approximately 30 percent following the announcement of its fourth-quarter financial results, indicating a positive market reaction to the company's profitability turnaround [1][2]. Financial Performance - The company reported a profit of $22.97 million, or $0.26 per share, for the fourth quarter, a significant improvement from a net loss of $7.19 million, or $0.08 per share, in the same period last year [1]. - Total revenue for the fourth quarter of 2025 was $644.0 million, up from $615.5 million in the fourth quarter of 2024, reflecting a year-over-year growth of 5 percent [2]. Stock Performance - The stock is currently trading at $38.25, which is an increase of 30.95 percent or $8.94 from the previous close of $29.35 on the New York Stock Exchange [2]. - Over the past year, the stock has traded within a range of $20.59 to $38.25 [2].

Core Insights - Labcorp reported strong financial performance for Q4 2025 and the full year, with revenue growth of over 7% and double-digit adjusted EPS growth, driven by its Diagnostics and Central Laboratory businesses [1][2] - The company provided guidance for 2026, projecting revenue between $14.61 billion and $14.79 billion, adjusted EPS between $17.55 and $18.25, and free cash flow of $1.24 billion to $1.36 billion [1][2] Financial Performance - Q4 2025 revenue was $3.52 billion, a 5.6% increase from Q4 2024's $3.33 billion; full-year revenue reached $13.95 billion, up 7.2% from $13.01 billion [1][2] - Adjusted EPS for Q4 was $4.07, compared to $3.45 in Q4 2024; full-year adjusted EPS was $16.44, up from $14.57 [1][2] - Free cash flow for Q4 was $490.3 million, down from $665.1 million in Q4 2024; full-year free cash flow increased to $1.21 billion from $1.10 billion [1][2] Strategic Developments - Labcorp completed several acquisitions, including assets from Empire City Laboratories, Incyte Diagnostics, and Community Health Systems, enhancing its service offerings [1][2] - The company announced plans to build a new 500,000 square foot Central Laboratory facility in Indiana, expected to begin construction in late 2026 [1][2] - Labcorp launched new consumer-initiated tests and expanded access to molecular residual disease testing for various cancers, as well as the first FDA-cleared blood test for Alzheimer's disease [1][2] Capital Allocation - In 2025, Labcorp invested $582 million in acquisitions, paid $240.7 million in dividends, and repurchased $450 million of its stock [1][2] - The company reported a cash and cash equivalents balance of $532.3 million and total debt of $5.58 billion at the end of Q4 2025 [1][2] Segment Performance - The Diagnostics Laboratories segment generated $2.73 billion in revenue for Q4 2025, a 5.5% increase from Q4 2024; adjusted operating income was $419.2 million, with a margin of 15.4% [2][4] - The Biopharma Laboratory Services segment reported $793 million in revenue for Q4 2025, a 3.4% increase, with adjusted operating income of $136.1 million and a margin of 17.2% [2][4]

Core Insights - Bavarian Nordic A/S reported preliminary financial results for 2025, with revenue of DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million [1][2] - The company achieved an EBITDA of DKK 2,542 million, resulting in an EBITDA margin of 41%, surpassing the latest guidance of approximately 40% [2][4] Financial Performance - Revenue breakdown for 2025 includes DKK 3,105 million from Public Preparedness and DKK 2,963 million from Travel Health, with Travel Health showing a 30% year-over-year growth [5][7] - The company’s core vaccines, rabies and TBE, contributed significantly to the revenue growth, with respective increases of 34% and 20% [5] - The chikungunya vaccine generated DKK 85 million in its first year of sales, exceeding guidance by DKK 10 million [5] 2026 Financial Guidance - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [6][7] - Revenue from Public Preparedness is anticipated to be between DKK 1,800 million and DKK 2,000 million, with DKK 1,300 million already secured through contracts [8] - Travel Health revenue is projected at approximately DKK 3,000 million, reflecting a 10% growth over the prior year [9][10] Research and Development - R&D spending for 2026 is capped at DKK 750 million, focusing on life-cycle management of the commercial portfolio and additional studies for the chikungunya vaccine [11] - Early-stage pipeline assets are expected to enter clinical development in 2027 [11] Capital Expenditure - CAPEX for 2026 is expected to be around DKK 250 million, with inventory levels anticipated to remain relatively unchanged [12]

Core Insights - Beach Cities Commercial Bank reported its financial results for the fourth quarter of 2025, highlighting robust growth and a focus on sustainable profitability [1] Financial Performance - The bank's net loss for Q4 2025 was $117.6k, a decrease from a profit of $14.5k in Q3 2025, but adjusted net income was $22.4k when excluding credit provisions [1] - Year-to-date loss for 2025 was $605.7k, significantly reduced by 87% from a loss of $4.5 million in 2024 [1] - Total deposits reached $143.5 million, marking a 9% increase from Q3 2025 and a 27% increase year-over-year [1] - Gross loans amounted to $144.1 million, reflecting a 12% growth from Q3 2025 and a 36% increase from the previous year [1] - Total assets grew to $176.7 million, a 13% increase from Q3 2025 and a 35% increase year-over-year [1] Asset Quality and Liquidity - The bank maintained a reserve for credit losses of $1.412 million, equating to 0.98% of total loans, with no delinquent or non-performing assets reported [1] - Total liquidity was high at $28.3 million, representing 16.02% of total assets, with additional contingent borrowing sources of $18.7 million [1] Interest Income and Expenses - Total interest income for Q4 2025 was $2.87 million, a 2.2% increase from Q3 2025, while interest expense decreased by 6.1% to $1.17 million [1] - The bank's net interest margin stood at 3.82% as of December 31, 2025, supported by an average loan yield of 7.69% [1] Operational Efficiency - Total operating expenses for Q4 2025 were $1.62 million, a 4.8% increase from Q3 2025, with a decrease in salaries and benefits expenses [1] - The bank's non-interest income from loan sales increased by 277% year-over-year, although gains from loan sales in Q4 2025 were lower than in Q3 2025 due to external factors [1] Future Outlook - The bank plans to raise up to $5 million through a private placement offering to support its growth momentum [1] - The appointment of a new President/CEO is expected to further enhance the bank's strategic direction and operational capabilities [1]

Core Insights - Service Corporation International (SCI) reported a strong financial performance for Q4 2025, with adjusted earnings per share (EPS) growing 8% year-over-year to $1.14 and a full-year adjusted EPS increase of 9% to $3.85 [1][2] - The company generated $966 million in adjusted operating cash flow for the full year, enabling strategic investments and returning $645 million to shareholders through dividends and share repurchases [1][2] - Looking ahead to 2026, SCI anticipates adjusted EPS growth within the long-term target range of 8% to 12% [2] Financial Performance - Q4 2025 revenue increased by $19 million, or 2%, to $1,111.5 million compared to Q4 2024, with full-year revenue rising by $123 million, or 3%, to $4,309.2 million [1][3] - Gross profit for Q4 2025 was $311.7 million, a 2% increase from Q4 2024, while full-year gross profit rose by $49 million, or 5%, to $1,140.1 million [1][3] - Net cash provided by operating activities decreased by $51.2 million to $212.9 million in Q4 2025, primarily due to higher cash interest and taxes [1][3] Segment Performance - Comparable preneed cemetery sales production grew by 2% in Q4 2025, with a full-year increase of $48 million, or 4% [1][5] - Comparable total funeral sales average increased by 3% in Q4 2025, while comparable preneed funeral sales production surged by 11% [1][5] - The company experienced a 0.9% increase in comparable cemetery revenue, driven by higher other revenue, despite a decline in core revenue [6] Capital Expenditures and Investments - In 2025, SCI invested approximately $101 million in acquisitions of 22 funeral homes and 2 cemeteries, alongside $79 million in real estate and new construction [1][2] - Total capital expenditures for 2025 amounted to $388.6 million, reflecting a $19.5 million increase from the previous year [6][7] Outlook for 2026 - The 2026 outlook for diluted EPS excluding special items is projected to be between $4.05 and $4.35, with net cash provided by operating activities expected to range from $1,005 million to $1,065 million [2][3] - Capital improvements at existing locations are budgeted at $135 million, with cemetery property development at $165 million [2][3]

Core Viewpoint - State Bank of India (SBI) is preparing to announce its financial results for the third quarter ending December 31, 2025, with significant anticipation from investors and analysts [1][2]. Financial Results Announcement - SBI's Central Board will convene on February 7, 2026, in Mumbai to review the financial results for Q3 FY26, among other agenda items [2]. - The trading window for SBI's securities has been closed for designated persons and their immediate relatives since January 1, 2026, and will reopen 48 hours after the financial results are declared [3]. Earnings Calls - Following the announcement of its Q3 FY26 results, SBI will hold an earnings call with analysts and institutional investors on February 7, 2026, at 5:15 p.m. The meeting will take place at the State Bank Bhavan Auditorium in Mumbai and will also be available via live webcast [4]. Recent Financial Performance - In Q2 FY2026, SBI reported a standalone net profit of Rs 20,159.67 crore, marking a 10% year-on-year increase from Rs 18,331.44 crore. This profit was bolstered by a Rs 4,593 crore gain from the sale of its stake in Yes Bank [5]. - Net interest income for the same period rose by 3% year-on-year to Rs 42,984.06 crore, up from Rs 41,619.54 crore [5]. Provisions and NPA - Provisions increased by 19.9% year-on-year to Rs 5,400 crore, up from Rs 4,506 crore. Operating profit, however, saw a decline of 6.8% to Rs 27,311 crore from Rs 29,294 crore [6]. - The gross non-performing assets (NPA) ratio improved to 1.73% from 1.83% quarter-on-quarter, while the net NPA ratio decreased to 0.42% from 0.47% [6]. Share Price Performance - SBI shares have experienced a 0.89% increase over the last five trading sessions and a 6.66% rise over the past month. In the last six months, the stock has appreciated by 33.96%, and year-to-date, it has gained 8.91%. Over the past year, the stock price has risen by 40% [7]. - As of 2:58 p.m. on Thursday, SBI shares were trading at Rs 1,072.50, reflecting a 0.40% increase, contrasting with a 0.52% decline in the benchmark Nifty 50 [8].

Financial Results Schedule - The company will publish its unaudited results for Q4 2025 and the full year 2025 on 06 February 2026 [1] - Audited results for 2025, along with a dividend proposal and agenda for the Annual General Meeting of Shareholders, will be released on 27 March 2026 [1] - Financial results for Q1 2026 are scheduled for 08 May 2026 [1] - Financial results for Q2 2026 will be published on 31 July 2026 [1] - The company will announce its financial results for Q3 2026 on 30 October 2026 [1] Annual General Meeting - The Annual General Meeting of Shareholders is set to take place on 23 April 2026 [1]

Core Viewpoint - Micron Technology reported record financial results for Q1 fiscal 2026, exceeding analysts' expectations, which has led to a significant increase in its stock price in after-hours trading [1][2]. Financial Performance - Micron achieved revenue of $13.64 billion in Q1 2026, marking a 56.7% year-over-year increase, surpassing analysts' expectations of $12.88 billion [4]. - The cloud memory business unit was the largest contributor to growth, generating $5.28 billion in sales, which represents a 99.5% increase compared to Q1 fiscal 2025 [4]. - Adjusted diluted earnings per share (EPS) were reported at $4.78, exceeding the estimated EPS of $3.94 [6]. - The company reported a record free cash flow of $3.9 billion, surpassing its previous record from Q4 2018 by over 20% [7]. Future Projections - Management projected Q2 2026 revenue between $18.3 billion and $19.1 billion, with adjusted diluted EPS expected to be between $8.22 and $8.62 [8].